Our results showed that mice vaccinated with the pcDNA3-mp53/pcDNA3-CD40L combined vaccine had small tumor volume (Fig. S4A) and a significantly higher survival rate (p<0.01) in comparison to other treatment groups (Fig. 3B). This evidence concerns the gene CD40LG and neoplasm.